Liu Yanxiang, Shi Yi, Guo Hongwei, Yu Cuntao, Qian Xiangyang, Wang Wei, Sun Xiaogang
Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Thorac Cardiovasc Surg. 2021 Jan;161(1):25-33. doi: 10.1016/j.jtcvs.2019.08.074. Epub 2019 Oct 4.
Moderate hypothermic circulatory arrest (MHCA) with antegrade cerebral perfusion (ACP) is safe and efficient in total arch replacement (TAR) and frozen elephant trunk (FET) for acute type A aortic dissection (ATAAD). Complications related to hypothermia and ischemia are inevitable, however. The aortic balloon occlusion (ABO) technique is performed to elevate the lowest nasopharyngeal temperature to 28°C and shorten the circulatory arrest time. In this study, we aimed to evaluate the efficacy of this new technique.
We reviewed the clinical data of patients with ATAAD who underwent TAR and FET, including 79 who underwent ABO and 109 who underwent MHCA/ACP.
Circulatory arrest time was significantly lower in the ABO group compared with the MHCA/ACP group (mean, 4.8 ± 1.2 minutes vs 18.4 ± 3.1 minutes; P < .001). The composite endpoint was comparable in the 2 groups (11.4% for ABO vs 13.8% for MHCA/ACP; P = .631). Fewer patients in the ABO group developed high-grade acute kidney injury (AKI) according to a modified RIFLE criterion (22.8% vs 36.7%; P = .041), and the rate of hepatic dysfunction was lower in the ABO group (11.4% vs 28.4%; P = .005). Multivariable logistic analysis showed that the ABO technique is protective against duration of ventilation >24 hours (odds ratio [OR], 0.455; 95% confidence interval [CI], 0.234-0.887; P = .021), hepatic dysfunction (OR, 0.218; 95% CI, 0.084-0.561; P = .002), and grade II-III AKI (OR, 0.432; 95% CI, 0.204-0.915; P = .028).
The ABO technique significantly shortens the circulatory arrest time in TAR and FET. Available clinical data suggest that it has a certain protective effect on the liver and kidney. Future large-sample studies are warranted to thoroughly evaluate this new technique.
在急性A型主动脉夹层(ATAAD)的全弓置换术(TAR)和冰冻象鼻术(FET)中,采用顺行性脑灌注(ACP)的中度低温循环停止(MHCA)是安全有效的。然而,与低温和缺血相关的并发症是不可避免的。主动脉球囊阻断(ABO)技术用于将最低鼻咽温度提高到28°C并缩短循环停止时间。在本研究中,我们旨在评估这项新技术的疗效。
我们回顾了接受TAR和FET的ATAAD患者的临床资料,包括79例行ABO的患者和109例行MHCA/ACP的患者。
与MHCA/ACP组相比,ABO组的循环停止时间显著缩短(平均4.8±1.2分钟对18.4±3.1分钟;P<.001)。两组的复合终点相当(ABO组为11.4%,MHCA/ACP组为13.8%;P=.631)。根据改良的RIFLE标准,ABO组发生重度急性肾损伤(AKI)的患者较少(22.8%对36.7%;P=.041),ABO组的肝功能障碍发生率较低(11.4%对28.4%;P=.005)。多变量逻辑分析显示,ABO技术可预防通气时间>24小时(优势比[OR],0.455;95%置信区间[CI],0.234-0.887;P=.021)、肝功能障碍(OR,0.218;95%CI,0.084-0.561;P=.002)和II-III级AKI(OR,0.432;95%CI,0.204-0.915;P=.028)。
ABO技术显著缩短了TAR和FET中的循环停止时间。现有临床资料表明,它对肝脏和肾脏有一定的保护作用。未来需要进行大样本研究以全面评估这项新技术。